PULIKE(SH:603566)2017-04-28 16:00Financial Performance - Operating revenue for the first quarter was CNY 132,228,870.11, representing a 13.46% increase year-on-year[7] - Net profit attributable to shareholders decreased by 23.72% to CNY 33,371,956.54, primarily due to a large government subsidy received in the same period last year[9] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 26.58% to CNY 29,721,142.52[7] - The weighted average return on equity decreased by 0.99 percentage points to 2.23%[7] - Total revenue for Q1 2017 was CNY 132,228,870.11, an increase of 13.9% compared to CNY 116,545,771.05 in the previous year[27] - Net profit for Q1 2017 was CNY 33,371,956.54, a decrease of 23.6% from CNY 43,750,598.06 in Q1 2016[28] - Earnings per share for Q1 2017 were CNY 0.10, down from CNY 0.14 in the previous year[29] - The total profit for Q1 2017 was ¥39,159,439.32, a decrease of 29.5% compared to ¥55,519,652.02 in the same period last year[33] - The net profit for Q1 2017 was ¥34,470,523.42, down 27.2% from ¥47,396,423.57 year-over-year[33] - The basic and diluted earnings per share for Q1 2017 were both ¥0.11, compared to ¥0.15 in the previous year, reflecting a decline of 26.7%[33] Revenue Breakdown - Revenue from pig vaccines (market sales) increased by 37.10% to CNY 28,998,299.33[14] - Revenue from poultry vaccines and antibodies grew by 57.69% to CNY 39,630,888.79[14] - Revenue from chemical drugs rose by 27.86% to CNY 35,727,568.48[14] Cash Flow and Investments - The net cash flow from operating activities was negative at CNY -6,249,219.45, a decrease of 128.07% compared to the same period last year[7] - Cash inflows from operating activities totaled ¥106,079,059.19, a decrease of 7.4% from ¥115,060,333.97 in the same period last year[36] - Cash inflows from investment activities were ¥221,886,003.86, up 120.1% from ¥100,761,938.63 year-over-year[36] - The net cash flow from investment activities was -¥56,968,268.64, worsening from -¥10,641,432.27 in the same period last year[36] - The total cash outflow from investment activities was ¥278,854,272.50, compared to ¥111,403,370.90 in the same period last year, indicating increased investment activity[39] Assets and Liabilities - The company's total assets increased by 1.28% to CNY 1,758,988,117.74 compared to the end of the previous year[7] - Total assets increased from CNY 1,736,825,580.03 to CNY 1,758,988,117.74, reflecting a growth of 1.27%[22] - Total current assets at the end of the period were CNY 1,051,559,607.91, a slight decrease of 1.4% from CNY 1,066,828,400.69 at the beginning of the year[25] - The company’s total liabilities decreased from CNY 255,905,876.92 to CNY 239,140,160.40, a reduction of 6.58%[22] - Total liabilities decreased to CNY 198,688,153.07 from CNY 212,909,606.23, reflecting a reduction of 6.7%[26] - Cash and cash equivalents decreased from CNY 428,628,319.95 to CNY 364,349,623.10, a decline of 15.00%[20] - Cash and cash equivalents at the end of the period were CNY 301,614,251.60, down from CNY 359,042,606.01 at the beginning of the year, a decline of 15.9%[24] - Inventory increased to CNY 53,967,281.02, up 16.3% from CNY 46,437,527.58 at the beginning of the year[25] - Long-term equity investments rose to CNY 329,616,972.14, a slight increase from CNY 324,111,720.05 at the start of the year[25] - Other receivables increased from CNY 7,286,352.84 to CNY 7,896,710.74, an increase of 8.36%[20] - Prepayments increased by 93.29% from CNY 1,713,739 to CNY 3,312,409 primarily due to increased advance payments for raw materials[16] Share-Based Payments - The company incurred a share-based payment expense of CNY 5,556,297.69 related to the 2016 stock incentive plan, impacting management expenses[9]